ELOCON LOTION Rx
Generic Name and Formulations:
Mometasone furoate 0.1%.
Merck & Co., Inc.
Indications for ELOCON LOTION:
≥12yrs: apply a few drops to affected areas once daily. Discontinue when control is achieved. Do not occlude.
<12yrs: not recommended.
Avoid use near eyes, on face, groin, or axillae. Do not use for diaper dermatitis. Risk of HPA axis suppression with high-potency steroids, prolonged use, application to large surface area, use of occlusive dressings, altered skin barrier, liver failure, young age; discontinue gradually, or reduce dose or potency if occurs. Increased risk of posterior subcapsular cataracts and glaucoma; monitor for visual symptoms. Treat infection if present; discontinue if infection persists or worsens. Reevaluate periodically. Pregnancy (Cat.C). Nursing mothers.
Burning, pruritus, skin atrophy, tingling/stinging, furunculosis, acneiform reaction, folliculitis; allergic contact dermatitis (discontinue if irritation occurs), HPA axis suppression (esp. in children); rare: Cushing's syndrome, hyperglycemia.
Oint—15g, 45g; Crm—15g, 50g; Lotion—30mL, 60mL
Endocrinology Advisor Articles
- Efficacy and Safety of Alirocumab in Diabetes Mellitus
- Safety of DPP-IV Inhibitor, Cardiovascular Events After ACS in Type 2 Diabetes
- Sex Hormone Levels May Affect Postmenopausal Heart Disease Risk
- Effect of Fructose, Allulose on Postprandial Glucose Regulation in Type 2 Diabetes
- Transgender Youth Not Willing to Delay Hormone Therapy for Fertility Preservation
- Diabetes Treatments
- Metformin May Decrease Colorectal Cancer Risk Among Males With Diabetes
- SGLT2 Inhibitor, GLP-1 Receptor Agonist Combination Treatment for Type 2 Diabetes: Expert Insights
- Semaglutide May Induce Weight Loss in Type 2 Diabetes Despite BMI
- FDA Clears Omnipod DASH System for Diabetes Management
- Single Blood Sample Highly Predictive for Subsequent Diabetes Diagnosis
- Plasma Methylglyoxal Levels Associated With CVD, Mortality in Type 2 Diabetes
- Adjunctive Metformin for Insulin Resistance in T1D: A Clinical Perspective
- AMA: Federal Government Must Tackle Rising Insulin Prices
- Diabetes Medication Reconciliation May Reduce Risk of ED Visits